An Open-Label Study of DCCR Tablet in Patients With PWS

NCT04086810 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2021-08-03

No results posted yet for this study

Summary

The primary objective of this study is to monitor the long-term safety of DCCR in PWS patients.

Conditions

Interventions

DRUG

DCCR

Once daily oral administration

Sponsors & Collaborators

  • Soleno Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
4 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-31
Primary Completion
2019-10-31
Completion
2019-10-31
FDA Drug
Yes

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04086810 on ClinicalTrials.gov